Scholtz (Pillar Biosciences) #NGDx18 Diagnostics for 25-30y. If it's valuable and does it well, the FDA is not a problem.
11:22am August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 Test utilization and regulation? When it happens 'at home'? The 'what ifs': it's going to happen; how to implement?
11:21am August 23rd 2018 via Twitter Web Client
Tsongalis #NGDx18 Into remarks to 'Disruptive technologies in lab medicine'. Wearables. Concepts of wellness. Microfluidics explosion.
11:20am August 23rd 2018 via Twitter Web Client
@Pillar_Bio own Manfred Scholz on a #NGDx18 disruptive technologies panel with Greg Tsongalis of @AMPath and… https://t.co/M0cQcE7bIa
11:18am August 23rd 2018 via Twitter for iPhone
Keyes #NGDx18 '16 PLoS One https://t.co/KT1KmEO5uK describing their small RNA adapters
9:43am August 23rd 2018 via Twitter Web Client
Keyes #NGDx18 Developed sterically blocked adapterswith a modified base, after screening some 250 candidates.
9:42am August 23rd 2018 via Twitter Web Client
Keyes #NGDx18 Electro-osmotic flow down a capillary, '14 ref https://t.co/riKUhjsxWa Nucleii can be separated from cytoplasm
9:37am August 23rd 2018 via Twitter Web Client
Keyes #NGDx18 Isotachophoresis, a discontinuous buffer with leading/trailing electrolytes. Sample as intermed ionic mobility
9:36am August 23rd 2018 via Twitter Web Client
Keys #NGDx18 Lays out the limitations of bulk methods. For total RNA run out on a Bioanalyzer: miRNA as a fraction of total RNA is small
9:29am August 23rd 2018 via Twitter Web Client
Dick Keys (Trilink) #NGDx18 Single-cell small RNA-seq by microfluidic chip isotachophoresis with sRNA library prep using modified adapters
9:24am August 23rd 2018 via Twitter Web Client
Q: How does CV risk cp to Leuk risk? Bolton #NGDx18 Lower but so prevalent, the absolute rates are higher
9:20am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 Also ped cancer survivors - high-dose radiation can observe high-risk CH.
9:18am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 High-risk pts are incidental findings. Now finding referrals from BMT survivors for relapse, seeing… https://t.co/PiUV0nHrGz
9:17am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 CH included in their std report. (Publication in-press at JCO) Shows workflow of pt management w/CH… https://t.co/HhIHBFIIno
9:16am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 36F met Ov ca, stable on carboplatin, prog cytopenia, TP53 mut. Launched a CH clinic, for either CVD or Leuk risk
9:15am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 A case - 72F w/new Dx of br ca, TP53 CH mutation. AZT, radiation, has a risk of CVD as survivor
9:13am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 Not only coronary artery disease but also stroke. Also shows data on mutations in skin of normal individuals
9:06am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 The driver genes are in leukemia, myeloid genes. Abs risk is low - 0.5%/year, reduced mortality. CH w/CV disease
9:03am August 23rd 2018 via Twitter Web Client
Bolton #NGDx18 CH: somatic mutations in leukemia-related genes in individuals w/no known hematologic disease. Sees… https://t.co/2JLMH41jEt
9:02am August 23rd 2018 via Twitter Web Client
Kelly Bolton (MSKCC) #NGDx18 The impact of oncologic therapy on the risk of clonal hematopoeisis and subsequent hematologic malignancy
9:00am August 23rd 2018 via Twitter Web Client
Q: Could it be CTCs confounding? Zehir #NGDx18 Definitely looking at it.
8:58am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 CH observed in 25% of adv cancer, can confound tumor-only seq in 5% of population.
8:56am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 ID of CH variants in cfDNA a VAF 1% for DNMT3A, but VAF 3% in buffy coat so it is CH.
8:55am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 Can confound NSCLC cfDNA results '18 ref https://t.co/zSj1xjsPLw
8:49am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 CH in Solid Tumor (CH-ST) mutations are 'absent in population databases', but CH mutations in ST is c… https://t.co/V2m1yZb3PO
8:45am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 'Ubiquitous' when looking with a sensitive sequencing approach (MSK-IMPACT, namely) '16 ref https://t.co/p8bijfnMBS
8:41am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 In cancer pts - 24%, 'CH is common and assoc'd with adverse outcomes' '17 ref https://t.co/rreaWCavkm
8:40am August 23rd 2018 via Twitter Web Client
Zehire #NGDx18 There is allelic pressure for certain clones to grow. A fn of age: '14 NEJM https://t.co/xfZMQNucEK and increased risk of CVD
8:38am August 23rd 2018 via Twitter Web Client
Zehir #NGDx18 Dep on the gene, can lead to full-blown leukemia '16 NEJM https://t.co/e0JYsEAGsT
8:37am August 23rd 2018 via Twitter Web Client
Ahmet Zehir (MSKCC) #NGDx18 Clonal hematopoeisis (CH) is common in cancer patients and can confound clinical genomic profiling
8:36am August 23rd 2018 via Twitter Web Client
Luis Diaz (MSKCC) Introductory remarks. #NGDx18 Clonal hematopoeisis is an entity, how to test / apply to end-pt.
8:35am August 23rd 2018 via Twitter Web Client
This ancient bone belonged to a child of two extinct human species | Science Magazine https://t.co/aMd0UNJxrn
8:25pm August 22nd 2018 via Hootsuite Inc.
Bionano Genomics Raises $20.6M in IPO, Starts Trading on Nasdaq | GenomeWeb https://t.co/yrNuDDdNWs
6:50pm August 22nd 2018 via Hootsuite Inc.
Benayed #NGDx18 They preferentially select low TMB samples for RNA-Seq. 14% MSK-Fusion Pos. 80% of these show clinical benefit.
4:58pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 40 uL of lysate saved in mineral oil, use QIAGEN kit for RNA from that. Shows list of fusions detec… https://t.co/0u5wNPLTCY
4:54pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 MSK-IMPACT driver-negative, go back to get RNA. Now they use lysate from DNA extraction; PE's Chema… https://t.co/wOsU2zrj0W
4:52pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 Shows interesting cases - a BCR-NTRK2 fusion, in exon 16 (not targeted in DNA). Another - 10% tumor… https://t.co/JS9pKxL0oA
4:49pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 qPCR 'preSeq' via Ct >29 'insufficient for testing'. Fail rate of 40% at Ct >29. Of 2310: 139 QNS,… https://t.co/4E5V7
4:46pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 RNA only captures exon-exon junction. Describes AMP method by ArcherDx. Their panel has 62 genes, t… https://t.co/eWb2Emq0Ty
4:45pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 Of 30K samples, 1,271 high-confidence in-frame fusions detected. Limitations for DNA fusion assay:… https://t.co/uuAvOZ6U37
4:42pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 LOXO NTRK ref '18 https://t.co/Qlowi6Yuk5 Describes MSK-IMPACT 70 introns of 20 re-arr genes.
4:41pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 Also therapeutic: targetable for TKIs '17 revihttps://www.ncbi.nlm.nih.gov/pubmed/28857077 LOXO-101 for TRK
4:39pm August 22nd 2018 via Twitter Web Client
Benayed #NGDx18 Gene fusions can be diagnostic (TEMPRSS2-ERG for prostate ca) and prognostic (RBM10-TFE2 for renal cell carcinoma)
4:38pm August 22nd 2018 via Twitter Web Client
Ryma Benayed (MSKCC) #NGDx18 Comprehensive DNA and RNA profiling in solid tumors for the detection of targetable kinase fusions
4:36pm August 22nd 2018 via Twitter Web Client
Beer #NGDx18 ASCO Review - ctDNA 'not yet' but on the horizon. '18 review https://t.co/M5E41mWFfd
2:36pm August 22nd 2018 via Twitter Web Client
Beer #NGDx18 ctDNA detection prognostic for I-O Rx in melanoma '17 ref https://t.co/MM42z6j1Wy PFS by ctDNA profile
2:33pm August 22nd 2018 via Twitter Web Client
Beer #NGDx18 Is there a compound or activity (tissue trauma) that would increase conc. of ctDNA in sample?
2:30pm August 22nd 2018 via Twitter Web Client
Beer #NGDx18 FFPE heterogeneity - they sample from may parts of the tissue. ctDNA in plasma increases after prostatectomy or DRE in CRC
2:29pm August 22nd 2018 via Twitter Web Client
Beer #NGDx18 5K samples, prevalence by day of testing, rates changed for ER testing '10 ref https://t.co/34fnD2Tp5M
2:26pm August 22nd 2018 via Twitter Web Client
Beer #NGDx18 Another study comparing PIK3CA status using BEAMing https://t.co/ZaNv5vP81b
2:25pm August 22nd 2018 via Twitter Web Client
